BTIG Research Reiterates Buy Rating for Harrow (NASDAQ:HROW)

Harrow (NASDAQ:HROW)‘s stock had its “buy” rating reaffirmed by stock analysts at BTIG Research in a note issued to investors on Friday,Benzinga reports. They presently have a $63.00 target price on the stock. BTIG Research’s price target indicates a potential upside of 51.81% from the stock’s previous close.

A number of other research analysts have also recently commented on HROW. Cantor Fitzgerald lowered their price target on Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. William Blair reaffirmed an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Harrow in a research note on Thursday, March 19th. Finally, Nomura downgraded Harrow to a “neutral” rating in a research note on Wednesday, March 18th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $69.86.

Harrow Stock Up 2.1%

NASDAQ HROW opened at $41.50 on Friday. The stock’s 50 day moving average is $40.71 and its 200 day moving average is $42.56. The company has a current ratio of 2.20, a quick ratio of 2.06 and a debt-to-equity ratio of 4.67. Harrow has a 12 month low of $21.12 and a 12 month high of $54.85. The stock has a market cap of $1.55 billion, a PE ratio of -244.10 and a beta of 0.31.

Institutional Trading of Harrow

A number of large investors have recently added to or reduced their stakes in HROW. University of Texas Texas AM Investment Management Co. bought a new stake in Harrow in the 4th quarter worth approximately $26,000. Raymond James Financial Inc. bought a new stake in Harrow in the 2nd quarter worth approximately $48,000. SBI Securities Co. Ltd. increased its stake in Harrow by 393.5% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock worth $52,000 after acquiring an additional 846 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of Harrow during the 3rd quarter valued at approximately $83,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Harrow by 25.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after purchasing an additional 369 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.